Emodin Reverses Gemcitabine Resistance of Pancreatic Cancer Cell Lines Through Inhibition of IKKβ/NF-κB Signaling Pathway

BACKGROUND: Pancreatic cancer is one of the most malignant tumors, and gemcitabine has been considered as the standard treatment and been widely utilized as a first-line drug for advanced pancreatic cancer, but gemcitabine-resistance always occurs after a short period of treatment. METHODS: Two panc...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, Hongfei, Huang, Zhen, Chen, Hui, Zhou, Bin, Liao, Yi, Wang, Zhaohong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537840/
https://www.ncbi.nlm.nih.gov/pubmed/33061461
http://dx.doi.org/10.2147/OTT.S253691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537840/
https://www.ncbi.nlm.nih.gov/pubmed/33061461
http://dx.doi.org/10.2147/OTT.S253691

Ejemplares similares